MEDI 547

Drug Profile

MEDI 547

Alternative Names: MEDI-547

Latest Information Update: 09 Feb 2011

Price : $50

At a glance

  • Originator MedImmune
  • Class Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 27 Jan 2011 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 30 Jun 2009 Phase-I clinical trials in Solid tumours in USA (IV)
  • 31 Jul 2007 Preclinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top